2022年EULAR关于IFN-I通路激活检测在临床研究和实践中测量、报告与应用的考虑要点
EULAR工作组遵循标准化操作流程,基于两项系统综述和专家意见制定2项总体原则和11条考虑要点,涉及IFN-I检测的术语、检测特征、报告规范及在诊断和结局评估中的临床应用,平均同意度总体较高。
要点
- PtC 1-4聚焦术语、检测特征和报告规范,以提高报告一致性和促进转化协作。
- PtC 5-11涉及诊断和结局评估的临床应用,包括疾病活动度、预后和治疗反应预测。
- 检测方法学协调和临床验证是研究议程的关键点。
核心结论
- IFN-I检测在风湿和肌肉骨骼疾病(RMDs)临床管理中具有较高实施潜力。
- 采纳这些考虑要点将促进IFN-I检测进入临床实践,并可能对风湿病学以外领域也有意义。
研究设计与样本
- 遵循EULAR标准化操作流程,成立包括风湿科医生、免疫学家、转化科学家和患者伙伴的工作组。
- 开展两项系统综述以解决方法学和临床问题。
- 基于检索证据和专家意见制定考虑要点,并确定证据水平和同意度。
主要发现
- 定义了2项总体原则和11条考虑要点。
- 第一组(PtC 1-4)涉及术语、检测特征和报告实践,以实现更一致的报告并促进转化和协作。
- 第二组(PtC 5-11)涉及诊断和结局评估的临床应用,包括疾病活动度、预后和治疗反应预测。
- 平均同意度总体较高,主要在PtC第一组和系统性红斑狼疮的临床应用方面。
关键数值与推荐
- 共2项总体原则和11条考虑要点。
- PtC 1-4涉及术语、检测特征和报告实践。
- PtC 5-11涉及诊断和结局评估的临床应用,包括疾病活动度、预后和治疗反应预测。
临床怎么用
- 原文未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Type I interferons (IFN-Is) play a role in a broad range of rheumatic and musculoskeletal diseases (RMDs), and compelling evidence suggests that their measurement could have clinical value, although testing has not progressed into clinical settings. OBJECTIVE: To develop evidence-based points to consider (PtC) for the measurement and reporting of IFN-I assays in clinical research and to determine their potential clinical utility. METHODS: EULAR standardised operating procedures were followed. A task force including rheumatologists, immunologists, translational scientists and a patient partner was formed. Two systematic reviews were conducted to address methodological and clinical questions. PtC were formulated based on the retrieved evidence and expert opinion. Level of evidence and agreement was determined. RESULTS: Two overarching principles and 11 PtC were defined. The first set (PtC 1-4) concerned terminology, assay characteristics and reporting practices to enable more consistent reporting and facilitate translation and collaborations. The second set (PtC 5-11) addressed clinical applications for diagnosis and outcome assessments, including disease activity, prognosis and prediction of treatment response. The mean level of agreement was generally high, mainly in the first PtC set and for clinical applications in systemic lupus erythematosus. Harmonisation of assay methodology and clinical validation were key points for the research agenda. CONCLUSIONS: IFN-I assays have a high potential for implementation in the clinical management of RMDs. Uptake of these PtC will facilitate the progress of IFN-I assays into clinical practice and may be also of interest beyond rheumatology.
引用
- Rodríguez-Carrio J, Burska A, Conaghan PG, et al. 2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice. Ann Rheum Dis. 2023. PMID: 36858821. doi:10.1136/ard-2022-223628
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。